Mass spectrometry has long been recognized for its analytical strengths, including high specificity, sensitivity, and the ability to measure multiple analytes simultaneously. For decades, these capabilities have made the technology an important tool in areas such as therapeutic drug monitoring, toxicology, endocrinology, newborn screening, and other areas of laboratory medicine.
More recently, however, discussions around clinical mass spectrometry have increasingly focused on a broader question: how can the technology be integrated more effectively into routine laboratory practice?
The evolution of clinical mass spectrometry is being shaped by multiple developments. Advances in automation, workflow standardization, and system integration are addressing some of the operational challenges that historically limited implementation outside specialized settings. Recent milestones, including the FDA’s CLIA “moderate complexity” designation for certain automated mass spectrometry assays, have further highlighted the field’s movement toward workflows designed for broader clinical laboratory use.
At the same time, emerging analytical approaches, including microflow LC-MS, are expanding interest in applications where greater specificity, multiplexing capability, or improved quantitative performance may be needed beyond traditional methods. Beyond established testing areas, researchers are also investigating new diagnostic possibilities, including mass spectrometry-based approaches for biomarker discovery and cancer diagnostics. Recent work exploring paper spray mass spectrometry for urine-based prostate cancer detection illustrates how the technology is being studied in emerging areas beyond its traditional clinical applications.
Together, these developments reflect a broader shift in how the field is approaching mass spectrometry. The conversation is moving beyond analytical capability alone to include questions of workflow, scalability, data interpretation, and clinical utility.
At ADLM 2026, several sessions reflect these ongoing themes, highlighting discussions around the continued evolution of established applications, emerging uses of mass spectrometry, and the ways laboratories are adapting the technology to meet changing diagnostic needs.
Expanding the role of an established technology
Mass spectrometry is already an established analytical approach in many areas of laboratory medicine. The current conversation is increasingly focused on where the technology can be applied next and what factors influence successful implementation.
In the session “Mass spectrometry: Transforming the clinical laboratory diagnosis” on July 28 at 7:30 AM, Uttam Garg, PhD, DABCC, DABFT, NRCC, FADLM, will discuss the principles of mass spectrometry and its applications across disciplines including clinical toxicology, therapeutic drug monitoring, endocrinology, metabolic and newborn screening, microbiology, and proteomics.
Dr. Garg brings a clinical laboratory perspective to the discussion as director of clinical chemistry and toxicology laboratories at Children’s Mercy Hospital in Kansas City and associate professor of pediatric pathology at the University of Missouri-Kansas City School of Medicine.
The range of applications represented in this session reflects the expanding footprint of mass spectrometry in clinical laboratories. While analytical performance remains central to the technology’s value, implementation considerations—including workflow complexity, laboratory expertise, and operational requirements—continue to influence adoption.
Automation, data interpretation, and emerging applications
As mass spectrometry becomes more integrated into laboratory environments, attention is also turning toward how workflows, automation, and data analysis may shape future applications.
The session “Off the beaten ion path: New directions for clinical mass spectrometry” on July 29 at 10:30 AM brings together perspectives spanning clinical chemistry, pathology, translational research, and laboratory informatics.
Speakers include Brody Foy, DPhil, whose research focuses on using large-scale clinical data to generate physiologic insights and improve patient outcomes; Michael Chen, MD, MSc, FRCPC, a clinical pathologist specializing in clinical chemistry and translational mass spectrometry at the University of British Columbia; and Daniel Holmes, MD, FRCPC, clinical professor of pathology and laboratory medicine at UBC and head and medical director of the Department of Pathology and Laboratory Medicine at St. Paul’s Hospital in Vancouver.
The topics covered in the session—including artificial intelligence and machine learning, automation, and emerging microbiology applications—reflect how the field is expanding beyond analytical measurement alone. As laboratories generate increasingly complex datasets, questions around interpretation, visualization, and clinical integration are becoming increasingly important.
Adapting mass spectrometry for time-sensitive clinical settings
Another area of discussion at ADLM 2026 is how mass spectrometry workflows can be adapted for settings where rapid turnaround is essential.
The session “Alternative sampling for rapid toxicology screening by mass spectrometry” on July 29 at 2:30 PM examines approaches aimed at addressing limitations of traditional LC-MS/MS workflows in acute care environments.
Moderated by William Clarke, PhD, MBA, DABCC, FADLM, professor of pathology at the Johns Hopkins University School of Medicine, the session includes presentations from experts working across clinical and forensic toxicology. Joshua DeBord, PhD, senior scientist at the Center for Forensic Science Research and Education, works in forensic toxicology and forensic chemistry, while Patrice Ohouo, PhD, NRCC, MLS(ASCP), is a certified toxicologist with experience in LC-MS method development, validation, and implementation for forensic and clinical drug testing.
The discussion will include approaches such as noninvasive toxicology screening, DART-MS/MS-based methods, and DESI MS-based screening strategies.
Toxicology represents one example of the broader challenge facing clinical mass spectrometry: balancing the analytical advantages of the technology with the speed, workflow requirements, and practical considerations of different care settings.
A field defined by expansion and adaptation
The trajectory of clinical mass spectrometry is not defined by a single technological milestone. Instead, it reflects an ongoing process of refinement—expanding established applications while exploring new ways to integrate advanced analytical capabilities into clinical workflows.
The themes emerging across ADLM 2026 reflect a field continuing to evolve: from questions of analytical performance toward broader considerations of implementation, automation, data interpretation, and clinical utility.
As laboratories continue to evaluate where mass spectrometry fits within modern diagnostics, the next phase of the technology will be shaped not only by what it can measure, but by how effectively those measurements can support clinical decision-making.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
